Bryn Mawr Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bryn Mawr Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-320	Closed	-$203K	–	429
2025 Q1	$203K	Buy	+320	New	+$220K	0.01%	374
2018 Q1	–	Sell	-11,542	Closed	-$5.16M	–	92
2017 Q4	$5.16M	Hold	11,542	–	–	6.77%	3
2017 Q3	$5.16M	Hold	11,542	–	–	5.37%	4
2017 Q2	$5.67M	Sell	11,542 -78	-0.7%	-$34.1K	6.39%	4
2017 Q1	$4.5M	Buy	+11,620	New	+$4.31M	4.63%	4

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bryn Mawr Capital Management's REGN Position: Q2 2025 in Review

Bryn Mawr Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 320 shares — an estimated $203K sold.

Bryn Mawr Capital Management first reported a position in REGN in Q1 2017 and held it in 5 quarters. The position peaked at $5.67M in Q2 2017. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Bryn Mawr Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Bryn Mawr Capital Management sold 320 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $203K.
Bryn Mawr Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2017 and held it in 5 quarters.
Bryn Mawr Capital Management's Regeneron Pharmaceuticals position peaked at $5.67M in Q2 2017.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Bryn Mawr Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.